Can switching from cigarettes to heated tobacco products reduce consequences of pulmonary infection?
Open Access
- 19 October 2024
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-10
Abstract
Rationale: While tobacco industry data suggests that switching from combustible cigarettes to heated tobacco products (HTPs), like IQOS, may reduce the users’ exposure to respiratory toxicants, it is not known if using HTPs impacts the outcomes of acute respiratory infections. Objectives: Does switching from cigarettes to HTPs improve responses to pulmonary infection. Methods: We conducted experiments in which 3 groups of mice were pre-exposed to cigarette smoke for 8 weeks, followed by 8-week exposure to (1) HTPs (tobacco product switching), (2) air (smoking cessation), or (3) continued exposure to cigarette smoke. Pulmonary bacterial clearance and surrogate markers of lung damage were assessed as study outcomes. Main results: Significantly compromised clearance of bacteria from the lungs post-acute challenge occurred in both the switching group and in mice continuously exposed to cigarette smoke. Bacterial clearance, inflammatory T-cell infiltration into the lungs, and albumin leak improved at 12 h post-acute challenge in the switching group compared to mice continuously exposed to cigarette smoke. Bacterial clearance, total lung immune-cell infiltration, inflammatory T-cell infiltration into the lungs, the content of total proteins in the BAL, and albumin leak measured post-acute challenge were compromised in the switching group compared to mice in the cessation group. Switching from cigarettes to HTPs did not improve lung myeloperoxidase and neutrophil elastase levels (markers for lung inflammation and damage), which, however, were significantly reduced in the cessation group. Conclusions: This study reveals only a modest improvement in respiratory infection outcomes after switching exposure from cigarettes to HTPs and significantly compromised outcomes compared to a complete cessation of exposure to all tobacco products.Keywords
Funding Information
- National Heart, Lung and Blood Institute of the National Institutes of Health (RO1HL142511)
- US Food and Drug Administration and National Cancer Institute (U54CA238110)
- National Cancer Institute, USA (P30CA016056)
This publication has 28 references indexed in Scilit:
- Global Patterns and Prevalence of Dual and Poly-Tobacco Use: A Systematic ReviewNicotine & Tobacco Research, 2021
- Acute Effects of Heated Tobacco Product (IQOS) Aerosol Inhalation on Lung Tissue Damage and Inflammatory Changes in the LungsNicotine & Tobacco Research, 2020
- A six-month systems toxicology inhalation/cessation study in ApoE−/− mice to investigate cardiovascular and respiratory exposure effects of modified risk tobacco products, CHTP 1.2 and THS 2.2, compared with conventional cigarettesFood and Chemical Toxicology, 2019
- Reduction in Exposure to Selected Harmful and Potentially Harmful Constituents Approaching Those Observed Upon Smoking Abstinence in Smokers Switching to the Menthol Tobacco Heating System 2.2 for 3 Months (Part 1)Nicotine & Tobacco Research, 2019
- Heat-Not-Burn Tobacco CigarettesJAMA Internal Medicine, 2017
- A systems toxicology approach for comparative assessment: Biological impact of an aerosol from a candidate modified-risk tobacco product and cigarette smoke on human organotypic bronchial epithelial culturesToxicology in Vitro, 2017
- Cigarette smoke attenuates phagocytic ability of macrophages through down-regulating Milk fat globule-EGF factor 8 (MFG-E8) expressionsScientific Reports, 2017
- Poly-tobacco use among adults in 44 countries during 2008–2012: Evidence for an integrative and comprehensive approach in tobacco controlDrug and Alcohol Dependence, 2014
- The composition of cigarette smoke determines inflammatory cell recruitment to the lung in COPD mouse modelsClinical Science, 2013
- How cigarette smoke skews immune responses to promote infection, lung disease and cancerNature Reviews Immunology, 2009